Education
Retatrutide Phase 3 Results: Major A1C Drops and 16.8% Weight Loss in Type 2 Diabetes
This Medical News Update covers late-stage trial results for retatrutide, an investigational weight-loss and diabetes drug from Eli Lilly. On March 19, 2026, Lilly announced positive topline findings from the phase 3 TRANSCEND-T2D-1 trial in adults with type 2 diabetes, showing A1C reductions of 1.7% to 2.0% depending on dose and average weight loss of 16.8% at the 12 mg dose. The script explains retatrutide’s three-hormone mechanism (GLP-1, GIP, and glucagon) versus Ozempic/Wegovy (GLP-1) and Mounjaro/Zepbound (GLP-1 + GIP), cautions that superiority claims require head-to-head trials, notes common side effects like nausea, vomiting, and diarrhea, and emphasizes that FDA approval, coverage, and pricing would still take significant time if future results remain strong.
00:00 Big Drug News
00:36 Trial Results Breakdown
01:09 Why It Works
01:38 Headlines Caveat
02:03 What It Means
02:25 Side Effects Tradeoffs
02:38 When It Arrives
02:54 Bigger Picture Wrap
03:07 Final Sign Off